Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Cash from Investing Activities came in at -$1.0 billion in Q1 2026, down 250.17% year-on-year from $692.6 million in Q1 2025, and up 76.81% quarter-over-quarter from -$4.5 billion in Q4 2025.

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$1.0 billion for Q1 2026.

  • Cash from Investing Activities for Q1 2026 came in at -$1.0 billion, down 250.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.3 billion (down 32.0% YoY), and the FY2025 annual result was -$23.6 billion, down 26.82% from the prior year.
  • Cash from Investing Activities came in at -$1.0 billion for Q1 2026 at Johnson & Johnson, up from -$4.5 billion in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $3.3 billion in Q2 2023 to a low of -$18.3 billion in Q2 2025.
  • The 5-year median for Cash from Investing Activities is -$1.3 billion (2024), against an average of -$3.7 billion.
  • Across the five-year window, Cash from Investing Activities plunged 1864.32% in 2022 and surged 191.22% in 2023, its largest moves.
  • Johnson & Johnson's Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then fell by 9.82% to -$1.3 billion in 2024, then sank by 239.77% to -$4.5 billion in 2025, then soared by 76.81% to -$1.0 billion in 2026.
  • The last three Cash from Investing Activities figures came in at -$1.0 billion (Q1 2026), -$4.5 billion (Q4 2025), and -$542.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -1.98 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -3.92 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -1.04 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -574.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -10.21 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 1.77 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 785.00 Mn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -131.00 Mn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 -1.04 Bn
Mar 29, 2026 -1.04 Bn
Dec 28, 2025 -4.49 Bn
Dec 28, 2025 -4.49 Bn
Sep 28, 2025 -542.00 Mn
Sep 28, 2025 -542.00 Mn
Jun 29, 2025 -18.26 Bn
Jun 29, 2025 -18.26 Bn
Mar 30, 2025 -297.00 Mn
Mar 30, 2025 -297.00 Mn
Dec 29, 2024 -1.32 Bn
Dec 29, 2024 -1.32 Bn
Sep 29, 2024 -3.13 Bn
Sep 29, 2024 -3.13 Bn
Jun 30, 2024 -13.69 Bn
Jun 30, 2024 -13.69 Bn
Mar 31, 2024 -464.00 Mn
Mar 31, 2024 -464.00 Mn
Dec 31, 2023 -1.20 Bn
Dec 31, 2023 -1.20 Bn